DRUGS IN PREGNANCY: ACKNOWLEDGING CHALLENGES - FINDING SOLUTIONS

Main Article Content

Gideon Koren
Stuart MacLeod
Donald Davis

Keywords

DRUGS, PREGNANCY

Abstract

Due to obvious ethical issues of experimenting drugs during fetal development, women and their unborn babies are commonly excluded from drug  trials.  As  a  result,  these  two  groups  of patients are commonly orphaned from the revolution in drug therapy witnessed in the last generation.

Abstract 301 | PDF Downloads 56

References

1. Dempsey D, Jacob P, Benowitz NZ. Accelerated metabolism of nicotine and cotinine in pregnant smokers. J PET 2002; 301: 594-8.
2. Heikkinen T, Ekblad U, Palo P, Laine K. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther 2003; 73: 330-7.
3. Bonari L, Bennett H, Einarson A, Koren G. Risks of untreated depression during pregnancy. Can Fam Physician 2004; 50: 37- 9.
4. Koren G. Maternal- Fetal Toxicology; A Clinician’s Guide. Marcel Dekker, NY, 3rd edition, 2001.
5. Elliott BD, Schenker S, Langer O, Johnson R, Prihoda T. Comparative placental transport of oral hypoglycemic agents in humans. Am J Obstet Gynecol 1994; 171: 653-60.
6. Langer O, et al. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med 2000; 343: 1134- 8.
7. Garcia-Bournissen F, Feig DS, Koren G. Maternal-Fetal transport of hypoglycemic drugs. Clin Pharmacokinet 2003; 42: 303- 13.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>